En español
NIDA

Clinical Trials Network

Young Opioid Abusers Benefit From Extended Buprenorphine-Naloxone Treatment

Reports on a study investigating the benefits of extended opioid maintenance therapy that included drug counseling and 12 weeks of therapy with buprenorphine and naloxone.

Dr. Phil Skolnick Now Leads NIDA's Medications Development Efforts

Announces the appointment of Dr. Phil Skolnick as NIDA’s director of the Division of Pharmacotherapies and Medical Consequences of Drug Abuse.

Low-Cost Incentives Improve Outcomes in Stimulant Abuse Treatment

Reports on a study investigating the use of incentives in the form of prizes to motivate outpatients to stay in behavioral therapy and remain drug free.

Intensive Interventions Reduce Risky Sexual Behaviors

Discusses research that compares multiple sessions of motivational and behavioral training with that of a single intervention among male and female substance abusers to reduce high-risk sexual behaviors.

Pages